Literature DB >> 27060348

Recombinant Salmonella typhimurium outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce interleukin (IL)-17/IL-23 in patients with reactive arthritis and undifferentiated spondyloarthropathy.

S Chaurasia1, A K Shasany2, A Aggarwal1, R Misra1.   

Abstract

In developing countries, one-third of patients with reactive arthritis (ReA) and undifferentiated spondyloarthropathy (uSpA) are triggered by Salmonella typhimurium. Synovial fluid mononuclear cells (SFMCs) of patients with ReA and uSpA proliferate to low molecular weight fractions (lmwf) of outer membrane proteins (Omp) of S. typhimurium. To characterize further the immunity of Omp of Salmonella, cellular immune response to two recombinant proteins of lmwf, OmpA and OmpD of S. typhimurium (rOmpA/D-sal) was assessed in 30 patients with ReA/uSpA. Using flow cytometry, 17 of 30 patients' SF CD8(+) T cells showed significant intracellular interferon (IFN)-γ to Omp crude lysate of S. typhimurium. Of these 17, 11 showed significantly more CD8(+) CD69(+) IFN-γ T cells to rOmpA-sal, whereas only four showed reactivity to rOmpD-sal. The mean stimulation index was significantly greater in rOmpA-sal than rOmpD-sal [3·0 (1·5-6·5) versus 1·5 (1·0-2·75), P < 0·005]. Similarly, using enzyme-linked immunospot (ELISPOT) in these 17 patients, the mean spots of IFN-γ-producing SFMCs were significantly greater in rOmpA-sal than rOmpD-sal [44·9 (3·5-130·7) versus 19·25 (6-41), P < 0·05]. SFMCs stimulated by rOmpA-sal produced significantly more proinflammatory cytokines than rOmpD-sal: IFN-γ [1·44 (0·39-20·42) versus 0·72 (0·048-9·15) ng/ml, P < 0·05], interleukin (IL)-17 [28·60 (6·15-510·86) versus 11·84 (6·83-252·62) pg/ml, P < 0·05], IL-23 [70·19 (15-1161·16) versus 28·25 (> 15-241·52) pg/ml, P < 0·05] and IL-6 [59·78 (2·03-273·36) versus 10·17 (0·004-190·19) ng/ml, P < 0·05]. The rOmpA-sal-specific CD8(+) T cell response correlated with duration of current synovitis (r = 0·53, P < 0·05). Thus, OmpA of S. typhimurium is a target of SF CD8(+) T cells and drives SFMC to produce increased cytokines of the IL-17/IL-23 axis which contribute to the pathogenesis of Salmonella-triggered ReA.
© 2016 British Society for Immunology.

Entities:  

Keywords:  antigens; arthritis; bacterial; cytokines; cytotoxic T cells

Mesh:

Substances:

Year:  2016        PMID: 27060348      PMCID: PMC4955008          DOI: 10.1111/cei.12799

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway.

Authors:  P Jeannin; T Renno; L Goetsch; I Miconnet; J P Aubry; Y Delneste; N Herbault; T Baussant; G Magistrelli; C Soulas; P Romero; J C Cerottini; J Y Bonnefoy
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

Review 2.  Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining.

Authors:  Anne Letsch; Carmen Scheibenbogen
Journal:  Methods       Date:  2003-10       Impact factor: 3.608

3.  Natural killer cell and gamma delta T cell alterations in enthesitis related arthritis category of juvenile idiopathic arthritis.

Authors:  Priyanka Gaur; Ramnath Misra; Amita Aggarwal
Journal:  Clin Immunol       Date:  2015-08-02       Impact factor: 3.969

Review 4.  Reactive arthritis.

Authors:  M Leirisalo-Repo
Journal:  Scand J Rheumatol       Date:  2005 Jul-Aug       Impact factor: 3.641

5.  Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis.

Authors:  R L Allen; G M Gillespie; F Hall; S Edmonds; M A Hall; B P Wordsworth; A J McMichael; P Bowness
Journal:  J Rheumatol       Date:  1997-09       Impact factor: 4.666

6.  Mechanism of assembly of the outer membrane of Salmonella typhimurium. Isolation and characterization of cytoplasmic and outer membrane.

Authors:  M J Osborn; J E Gander; E Parisi; J Carson
Journal:  J Biol Chem       Date:  1972-06-25       Impact factor: 5.157

7.  Salmonella enterica induces joint inflammation and expression of interleukin-17 in draining lymph nodes early after onset of enterocolitis in mice.

Authors:  Mariángeles Noto Llana; Sebastián Hernán Sarnacki; María Victoria Vázquez; Alejandra Sonia Gartner; Mónica Nancy Giacomodonato; María Cristina Cerquetti
Journal:  Infect Immun       Date:  2012-04-09       Impact factor: 3.441

8.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

9.  The C-terminal domain of Salmonella enterica serovar typhimurium OmpA is an immunodominant antigen in mice but appears to be only partially exposed on the bacterial cell surface.

Authors:  Shiva P Singh; Yvonne U Williams; Stephanie Miller; Hiroshi Nikaido
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression.

Authors:  Bina Menon; Nicola J Gullick; Gina J Walter; Megha Rajasekhar; Toby Garrood; Hayley G Evans; Leonie S Taams; Bruce W Kirkham
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

View more
  9 in total

1.  Epidemiology: Time to revisit the concept of reactive arthritis.

Authors:  Ramnath Misra; Latika Gupta
Journal:  Nat Rev Rheumatol       Date:  2017-05-11       Impact factor: 20.543

Review 2.  Reactive arthritis occurring after COVID-19 infection: a narrative review.

Authors:  Maroua Slouma; Maissa Abbes; Takoua Mehmli; Rim Dhahri; Leila Metoui; Imen Gharsallah; Bassem Louzir
Journal:  Infection       Date:  2022-06-02       Impact factor: 7.455

3.  Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis.

Authors:  Julia Manasson; Nan Shen; Helga R Garcia Ferrer; Carles Ubeda; Isa Iraheta; Adriana Heguy; Joan M Von Feldt; Luis R Espinoza; Abraham Garcia Kutzbach; Leopoldo N Segal; Alexis Ogdie; Jose C Clemente; Jose U Scher
Journal:  Arthritis Rheumatol       Date:  2018-01-03       Impact factor: 10.995

Review 4.  Microbial-derived antigens and metabolites in spondyloarthritis.

Authors:  Katharine Lu Yang; Alannah Lejeune; Gregory Chang; Jose U Scher; Sergei B Koralov
Journal:  Semin Immunopathol       Date:  2021-02-10       Impact factor: 11.759

5.  Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice.

Authors:  Lianjun Yang; Bin Liu; Junchi Zheng; Jincheng Huang; Qinghao Zhao; Jinshi Liu; Zhihai Su; Min Wang; Zhifei Cui; Tingxuan Wang; Weicong Zhang; Qingchu Li; Hai Lu
Journal:  Front Cell Infect Microbiol       Date:  2019-03-04       Impact factor: 5.293

Review 6.  Microbes, helminths, and rheumatic diseases.

Authors:  Francisco Airton Castro Rocha; Ana Margarida Duarte-Monteiro; Licia Maria Henrique da Mota; Ana Carolina Matias Dinelly Pinto; João Eurico Fonseca
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-05-07       Impact factor: 4.098

Review 7.  Treatment of reactive arthritis with biological agents: a review.

Authors:  Huiqiong Zeng; Baiwei Luo; Yue Zhang; Zhongyu Xie; Zhizhong Ye
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

Review 8.  Reactive Arthritis: Update.

Authors:  Ibtissam Bentaleb; Kawther Ben Abdelghani; Samira Rostom; Bouchra Amine; Ahmed Laatar; Rachid Bahiri
Journal:  Curr Clin Microbiol Rep       Date:  2020-09-26

9.  Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach.

Authors:  Anukriti Verma; Shivani Sharda; Bhawna Rathi; Pallavi Somvanshi; Bimlesh Dhar Pandey
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.